Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
PCSA 
Processa Pharmaceuticals Inc (PCSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: PCSA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.08% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.27M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1 | Beta 1.09 | 52 Weeks Range 0.15 - 1.33 | Updated Date 12/9/2025 |
52 Weeks Range 0.15 - 1.33 | Updated Date 12/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -129.94% | Return on Equity (TTM) -270.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9710566 | Price to Sales(TTM) - |
Enterprise Value 9710566 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 56644223 | Shares Floating 51018885 |
Shares Outstanding 56644223 | Shares Floating 51018885 | ||
Percent Insiders 10.73 | Percent Institutions 7.81 |
Upturn AI SWOT
Processa Pharmaceuticals Inc
Company Overview
History and Background
Processa Pharmaceuticals Inc. was founded in 2017. Its primary focus is on developing and commercializing novel cancer therapies. A significant milestone includes the progression of its lead drug candidate through clinical trials. The company has evolved by strategically acquiring and developing a pipeline of promising oncology assets.
Core Business Areas
- Oncology Drug Development: Processa Pharmaceuticals Inc. is dedicated to the research, development, and potential commercialization of innovative drugs targeting various forms of cancer. This involves extensive preclinical and clinical trial work to demonstrate safety and efficacy.
Leadership and Structure
The company is led by a management team with experience in drug development and the pharmaceutical industry. Specific details on the current leadership team and organizational structure would require access to real-time company filings and internal documents.
Top Products and Market Share
Key Offerings
- Product Name 1: As of current publicly available information, Processa Pharmaceuticals Inc. is focused on advancing its lead drug candidate, PC1412, a novel molecule intended for the treatment of certain types of cancer. Detailed market share data or revenue figures for this specific product are not yet available as it is still in development. Competitors would include other pharmaceutical companies developing similar targeted therapies or immunotherapies for the same cancer indications.
Market Dynamics
Industry Overview
The oncology drug market is highly competitive and rapidly evolving, driven by advancements in understanding cancer biology, targeted therapies, immunotherapies, and personalized medicine. There is a constant demand for new and more effective treatments with improved safety profiles.
Positioning
Processa Pharmaceuticals Inc. positions itself by focusing on unmet needs in specific cancer indications with novel therapeutic approaches. Its competitive advantage lies in its proprietary drug candidates and its focused development strategy.
Total Addressable Market (TAM)
The total addressable market for oncology drugs is exceptionally large, measured in hundreds of billions of dollars globally and is projected to continue growing significantly. Processa Pharmaceuticals Inc. aims to capture a portion of this market by addressing specific cancer types where its pipeline candidates demonstrate a distinct benefit.
Upturn SWOT Analysis
Strengths
- Focus on a critical and growing market (oncology)
- Development of novel drug candidates
- Experienced management team (assumed based on industry standards)
- Potential for significant therapeutic impact
Weaknesses
- Early-stage development company with no approved products
- High R&D costs and long development timelines
- Reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Advancements in cancer research and biotechnology
- Potential for strategic partnerships and collaborations
- Expansion into different cancer indications
- Growing demand for innovative cancer treatments
Threats
- Clinical trial failures
- Regulatory hurdles and approval delays
- Competition from established and emerging biopharmaceutical companies
- Pricing and reimbursement challenges
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- There are numerous companies in the oncology space. Identifying Processa's direct competitors depends on the specific cancer indications its pipeline targets. Without this specificity, a comprehensive list is not feasible. However, major players in oncology drug development include Pfizer (PFE), Merck & Co. (MRK), Bristol Myers Squibb (BMY), and Novartis (NVS), among many others in the biopharmaceutical sector.
Competitive Landscape
Processa Pharmaceuticals Inc. faces intense competition from large, established pharmaceutical companies with significant resources and extensive R&D pipelines. Its advantage lies in its ability to focus on niche areas or develop novel mechanisms of action that may be overlooked or are too early-stage for larger companies to pursue.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Processa Pharmaceuticals Inc. has been characterized by its establishment, fundraising efforts, and the progression of its lead drug candidates through preclinical and early clinical stages.
Future Projections: Future growth projections are heavily dependent on the successful outcome of clinical trials, regulatory approvals, and eventual commercialization of its drug pipeline. Analyst projections, if available, would be contingent on these key development milestones.
Recent Initiatives: Recent initiatives would likely include advancements in clinical trial enrollment, data analysis from ongoing studies, and potential strategic partnerships for further development or commercialization.
Summary
Processa Pharmaceuticals Inc. is an early-stage biopharmaceutical company focused on developing innovative cancer therapies. Its strength lies in its targeted approach to oncology and potential for novel drug development. However, it faces significant weaknesses inherent to its stage, including high R&D costs, reliance on clinical trial success, and limited financial resources. The company's future growth is contingent on navigating regulatory hurdles and demonstrating clinical efficacy to secure market entry and attract potential partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company public filings (e.g., SEC filings)
- Industry research reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. It is not financial advice. Investors should conduct their own due diligence before making any investment decisions. Specific financial figures and market share data are subject to change and may not be exhaustive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Processa Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Hanover, MD, United States | ||
IPO Launch date 2017-10-10 | CEO & Director Mr. George K. Ng Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | |
Full time employees 10 | |||
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.